Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 2
1970 2
1972 4
1973 1
1974 1
1975 4
1976 5
1977 3
1978 1
1979 2
1980 2
1981 7
1982 4
1983 3
1984 2
1985 2
1986 2
1987 2
1988 2
1989 4
1990 7
1991 2
1992 3
1993 2
1994 8
1995 3
1996 3
1997 2
1998 6
1999 5
2000 2
2001 7
2002 3
2003 5
2004 6
2005 14
2006 10
2007 12
2008 16
2009 19
2010 16
2011 28
2012 38
2013 38
2014 30
2015 25
2016 28
2017 25
2018 17
2019 8
2020 8
2021 12
2022 11
2023 5
2024 5
2025 4
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

437 results

Results by year

Filters applied: . Clear all
Page 1
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine.
Nagaraju GP, Saddala MS, Foote JB, Khaliq AM, Masood A, Golivi Y, Bandi DSR, Sarvesh S, Reddy SP, Switchenko J, Carstens JL, Akce M, Herting C, Alese OB, Yoon KJ, Manne U, Bhasin MK, Lesinski GB, Sukhatme VP, El-Rayes BF. Nagaraju GP, et al. Cell Rep Med. 2025 Jan 21;6(1):101881. doi: 10.1016/j.xcrm.2024.101881. Epub 2024 Dec 26. Cell Rep Med. 2025. PMID: 39730001 Free PMC article. Clinical Trial.
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.
Perez KJ, Dias Costa A, Jordan A, Karasic TB, Elganainy D, Kim S, Yuan C, Gui DY, Tan R, Hong SC, Wang X, Cristea S, Coleman E, Truitt M, Oh TG, Zheng H, Furniss CS, Brais L, Bird A, Remland J, Gocheva V, Thalappillil JS, Anderson M, Cleary JM, Enzinger A, Giannakis M, Ng K, Rubinson DA, Schlechter B, Surana R, Singh H, Abrams T, Teitelbaum U, Izgur N, Allen E, Winter PS, Raghavan S, Yeh JJ, Von Hoff D, Liddle C, Downes M, Evans RM, O'Dwyer P, Aguirre A, Nowak JA, Wolpin BM. Perez KJ, et al. Nat Cancer. 2026 Jun;7(6):928-943. doi: 10.1038/s43018-026-01165-8. Epub 2026 May 25. Nat Cancer. 2026. PMID: 42185478 Free PMC article. Clinical Trial.
Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer.
Easty D, McDermott R, Murphy AG, Grogan L, Morris PG, Breathnach OS, Egan K, Toomey S, Horgan A, Power D, Osman N, Parker I, Donachie V, Shevlin A, Barrett A, Nolan M, Marron J, Farr CJ, Hennessy BT. Easty D, et al. BMC Cancer. 2026 Jan 15;26(1):255. doi: 10.1186/s12885-025-14512-2. BMC Cancer. 2026. PMID: 41535788 Free PMC article. Clinical Trial.
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer.
Viniotis AF, Jameson GS, Wertheim BC, Roe DJ, Lee K, Tsai FY, Gordon MS, Sharma S, Guarnieri CM, Snyder CE, Thosani AJ, Amini A, Sckolnik SE, Garrick JM, Korn RL, Rahmanuddin S, Evans RM, Downes M, Truitt M, Von Hoff DD, Borazanci EH. Viniotis AF, et al. Oncologist. 2026 Jun 6;31(7):oyag232. doi: 10.1093/oncolo/oyag232. Oncologist. 2026. PMID: 42268676 Free PMC article. Clinical Trial.
Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows.
Hymøller L, Jensen SK. Hymøller L, et al. Domest Anim Endocrinol. 2017 Apr;59:44-52. doi: 10.1016/j.domaniend.2016.11.002. Epub 2016 Nov 16. Domest Anim Endocrinol. 2017. PMID: 27940098 Clinical Trial.
In cattle, there are 2 significant forms of vitamin D: ergocalciferol (ERG) from fungi on roughage and cholecalciferol (CHO) from vitamin supplements or endogenous synthesis in the skin. ...
In cattle, there are 2 significant forms of vitamin D: ergocalciferol (ERG) from fungi on roughage and cholecalciferol (CHO) from vit …
Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial.
Miskulin DC, Majchrzak K, Tighiouart H, Muther RS, Kapoian T, Johnson DS, Weiner DE. Miskulin DC, et al. J Am Soc Nephrol. 2016 Jun;27(6):1801-10. doi: 10.1681/ASN.2015040468. Epub 2015 Dec 17. J Am Soc Nephrol. 2016. PMID: 26677862 Free PMC article. Clinical Trial.
We conducted a double-blind, placebo-controlled, randomized clinical trial to assess the effects of supplementation with ergocalciferol on epoetin utilization and other secondary outcomes in patients on hemodialysis with serum 25(OH)D <30 ng/ml. In all, 276 patients wer …
We conducted a double-blind, placebo-controlled, randomized clinical trial to assess the effects of supplementation with ergocalciferol …
A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
Susantitaphong P, Nakwan S, Peerapornratana S, Tiranathanagul K, Katavetin P, Srisawat N, Praditpornsilpa K, Eiam-Ong S. Susantitaphong P, et al. BMC Nephrol. 2017 Jan 14;18(1):19. doi: 10.1186/s12882-017-0436-6. BMC Nephrol. 2017. PMID: 28088187 Free PMC article. Clinical Trial.
Patients were randomly assigned to receive 12-week treatment with oral ergocalciferol plus placebo (n = 36) or oral ergocalciferol plus calcitriol (n = 32). RESULTS: The mean baseline values of UPCR of both groups were comparable (3.6 3.8 g/g in combined group and …
Patients were randomly assigned to receive 12-week treatment with oral ergocalciferol plus placebo (n = 36) or oral ergocalciferol …
Standard and high dose ergocalciferol regimens for treatment of hypovitaminosis D in epileptic children and adolescents.
Vichutavate S, Suwanpakdee P, Likasitthananon N, Numbenjapon N, Nabangchang C, Phatarakijnirund V. Vichutavate S, et al. J Pediatr Endocrinol Metab. 2022 Oct 4;35(11):1369-1376. doi: 10.1515/jpem-2022-0197. Print 2022 Nov 25. J Pediatr Endocrinol Metab. 2022. PMID: 36190481 Clinical Trial.
We aimed to compare the effect of two ergocalciferol regimens given for 90 days. METHODS: Epileptic patients aged 5-18 years who received at least one antiepileptic drug (AED) for more than 6 months and had serum 25-OHD <30 ng/mL were randomized to receive 20,000 IU/10 …
We aimed to compare the effect of two ergocalciferol regimens given for 90 days. METHODS: Epileptic patients aged 5-18 years who rece …
437 results